ATE391727T1 - Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors - Google Patents
Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptorsInfo
- Publication number
- ATE391727T1 ATE391727T1 AT03796966T AT03796966T ATE391727T1 AT E391727 T1 ATE391727 T1 AT E391727T1 AT 03796966 T AT03796966 T AT 03796966T AT 03796966 T AT03796966 T AT 03796966T AT E391727 T1 ATE391727 T1 AT E391727T1
- Authority
- AT
- Austria
- Prior art keywords
- human orexin
- receptor
- present
- orexin
- identifying modulators
- Prior art date
Links
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 101000598921 Homo sapiens Orexin Proteins 0.000 abstract 1
- 102000008834 Orexin receptor Human genes 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2864—Sleep disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43341102P | 2002-12-13 | 2002-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE391727T1 true ATE391727T1 (de) | 2008-04-15 |
Family
ID=32595183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03796966T ATE391727T1 (de) | 2002-12-13 | 2003-12-11 | Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7618786B2 (de) |
| EP (1) | EP1572133B1 (de) |
| JP (1) | JP2006518709A (de) |
| AT (1) | ATE391727T1 (de) |
| AU (1) | AU2003297896A1 (de) |
| CA (1) | CA2509215A1 (de) |
| DE (1) | DE60320302T2 (de) |
| DK (1) | DK1572133T3 (de) |
| ES (1) | ES2303912T3 (de) |
| WO (1) | WO2004054510A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4094050B2 (ja) | 2004-03-01 | 2008-06-04 | アクテリオン ファーマシューティカルズ リミテッド | 置換１，２，３，４−テトラヒドロイソキノリン誘導体 |
| EP4438041A3 (de) | 2016-02-04 | 2025-01-01 | Takeda Pharmaceutical Company Limited | Substituierte piperidinverbindung und verwendung davon |
| EP3594203B1 (de) | 2017-03-08 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Substituierte pyrrolidinverbindung und verwendung davon |
| JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| JP6574918B1 (ja) | 2017-08-03 | 2019-09-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP7189140B2 (ja) | 2017-08-03 | 2022-12-13 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP7413261B2 (ja) | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP3816154B1 (de) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung und anwendung davon |
| US12091410B2 (en) | 2018-12-12 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| CN118271298A (zh) | 2019-01-31 | 2024-07-02 | 武田药品工业株式会社 | 杂环化合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589351A (en) * | 1994-12-06 | 1996-12-31 | Nps Pharmaceuticals, Inc. | Fluorescence detection apparatus |
| CA2408343A1 (en) | 2000-05-11 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
-
2003
- 2003-12-11 JP JP2004560786A patent/JP2006518709A/ja active Pending
- 2003-12-11 EP EP03796966A patent/EP1572133B1/de not_active Expired - Lifetime
- 2003-12-11 US US10/537,732 patent/US7618786B2/en not_active Expired - Lifetime
- 2003-12-11 AU AU2003297896A patent/AU2003297896A1/en not_active Abandoned
- 2003-12-11 DK DK03796966T patent/DK1572133T3/da active
- 2003-12-11 ES ES03796966T patent/ES2303912T3/es not_active Expired - Lifetime
- 2003-12-11 CA CA002509215A patent/CA2509215A1/en not_active Abandoned
- 2003-12-11 WO PCT/US2003/039491 patent/WO2004054510A2/en not_active Ceased
- 2003-12-11 AT AT03796966T patent/ATE391727T1/de active
- 2003-12-11 DE DE60320302T patent/DE60320302T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60320302D1 (de) | 2008-05-21 |
| AU2003297896A1 (en) | 2004-07-09 |
| US20060035285A1 (en) | 2006-02-16 |
| WO2004054510A2 (en) | 2004-07-01 |
| EP1572133B1 (de) | 2008-04-09 |
| EP1572133A4 (de) | 2007-05-02 |
| CA2509215A1 (en) | 2004-07-01 |
| JP2006518709A (ja) | 2006-08-17 |
| ES2303912T3 (es) | 2008-09-01 |
| US7618786B2 (en) | 2009-11-17 |
| DK1572133T3 (da) | 2008-07-14 |
| DE60320302T2 (de) | 2009-05-20 |
| WO2004054510A3 (en) | 2007-01-18 |
| EP1572133A2 (de) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69932832D1 (de) | Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung | |
| ATE437652T1 (de) | Verwendung von hmgb1 zur aktivierung dendritischer zellen | |
| ATE405586T1 (de) | Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins | |
| MY141215A (en) | Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, method and uses | |
| IL168050A (en) | Il-1 receptor based antagonists and methods of making them and reagents for use therein | |
| DE60320302D1 (de) | Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors | |
| DE60129799D1 (de) | Verfahren zur steigerung des haarwuchses durch wnt polypeptid | |
| DE60324430D1 (de) | Methode um rekombinante proteine in cho zellen zu exprimieren | |
| ATE393237T1 (de) | Mittel und verfahren zur in-vitro-bestimmung von camp | |
| BR9912455A (pt) | ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória | |
| ATE506370T1 (de) | Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen | |
| DE60232827D1 (de) | Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen | |
| ATE443296T1 (de) | Methoden und system zur identifikation und charakterisierung von peptiden und ihrer funktionellen beziehung mittels berechnung von korrelation | |
| DE60325194D1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
| ATE513033T1 (de) | Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen | |
| DE60025480D1 (de) | Methoden zur identifizierung von modulatoren wechselwirkender proteine | |
| EP1685379A4 (de) | Verfahren zur identifizierung von zelloberflächen-rezeptorprotein-modulatoren | |
| WO2003059932A3 (en) | Methods of inducing or enhancing connective tissue repair | |
| DE60011785D1 (de) | Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen | |
| AU6318301A (en) | Cng3b: a novel cyclic nucleotide-gated cation channel | |
| SE9602822D0 (sv) | New receptor | |
| DE60128104D1 (de) | Cng2b: ein putativer humaner zyklische-nukleotid abhängiger ionenkanal | |
| DE602004031116D1 (de) | Von hla-klasse-ii-molekülen präsentierte ssx-2-peptide | |
| ATE535605T1 (de) | Autoinduzierbarer natriumphosphat-symporter- promotor aus pichia pastoris und verfahren zur herstellung von rekombinantem protein unter verwendung davon | |
| MXPA03011260A (es) | Receptor acoplado a proteina g y usos del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1572133 Country of ref document: EP |